Drug intelligence / Profile preview

IGN003

Development stage: Discontinued
Lead developer: ImmunGene

Overview

IGN003 is an investigational biologic developed by ImmunGene, Inc., likely an antibody-interferon fusion protein based on the company's platform, targeted at cancer immunotherapy. It was pursued for oncology applications but has been discontinued globally across its development programs. No specific mechanism of action, clinical data, or detailed indications beyond neoplasms have been publicly detailed in available sources.

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on IGN003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGN003.

Explore the full profile